StockMacro
Menu

Atrium Therapeutics

$6.92 -47% in 6 monthsMarket cap $149.3M

RNA on XNAS, Health Care, Atrium Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 24% to $15.3M but the stock fell 90% in a year while short sellers hold 17% of shares.

  • GoodNet cash $232.1M, the same as cash, so no net debt

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Industry
Pharmaceutical preparations (Health Care)
Employees
391
Website
aviditybiosciences.com
Listed
Nasdaq, US
Last results
12 Nov 2026
Next results
expected around 13 May 2027 (an estimate: a year ago it reported on 14 May 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $15.3M, net loss $4.3M.
Quarter to 31 Mar 2025: revenue $1.6M, net income -$7.4MQuarter to 31 Mar 2025: revenue $1.6M, net income -$7.4MQuarter to 30 Jun 2025: revenue $3.8M, net income -$12.9MQuarter to 30 Jun 2025: revenue $3.8M, net income -$12.9MQuarter to 30 Sep 2025: revenue $12.3M, net income -$37KQuarter to 30 Sep 2025: revenue $12.3M, net income -$37KQuarter to 31 Mar 2026: revenue $19.6M, net income -$16.6MQuarter to 31 Mar 2026: revenue $19.6M, net income -$16.6MQuarter to 30 Jun 2026: revenue $3.0M, net income -$20.2MQuarter to 30 Jun 2026: revenue $3.0M, net income -$20.2MQuarter to 30 Sep 2026: revenue $15.3M, net income -$4.3MQuarter to 30 Sep 2026: revenue $15.3M, net income -$4.3M
31 Mar 2025RevenueNet incomeNet losstallest bar $20.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$15.3M-$4.3M
30 Jun 2026$3.0M-$20.2M
31 Mar 2026$19.6M-$16.6M
30 Sep 2025$12.3M-$37K
30 Jun 2025$3.8M-$12.9M
31 Mar 2025$1.6M-$7.4M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. – –
Revenue growthRevenue of the last 12 months compared with the 12 months before. – +11%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. – –
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). – –
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 73.2%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. – – -25.0%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. – – -18.2%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. – -58.8%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – –
CashCash, cash equivalents and short-term investments on the latest balance sheet. $232.1M $0
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$232.1M (net cash) –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $9.50
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. – 19.3
P/SPrice to sales: market cap divided by revenue of the last 12 months. – 5.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 5.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 0.73 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Atrium TherapeuticsRNA (this company) $149.3M––––
Eledon PharmaceuticalsELDN $150.3Mloss–––
BridgeBio Oncology TherapeuticsBBOT $145.3Mloss–––
Oramed PharmaceuticalsORMP $155.2M––––
ALX OncologyALXO $137.0Mloss–––
Abeona TherapeuticsABEO $165.3Mloss3.5–-160%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

–

No data for this company

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

-4.6%

146 13F filers vs 153

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

65%

14.0M shares held by 13F filers (30 Sep 2026) of 21.6M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

17%

3.7M shares sold short (30 Oct 2026) of 21.6M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

16.1

3.7M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+0.6%

3.7M shares sold short in the report before, 3.7M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

62%

62% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+24%

$15.3M vs $12.3M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$190K

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

9

9 articles in the last 7 days; its usual week has 0 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

–

9 articles in the last 7 days; its usual week has 0: fewer than one, so there is nothing to compare with.

Price $6.92 on 20 Nov 2026, -90% over 12 months (12-month range $6.43 to $72.93)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Revenue per quarter. Revenue $15.3M in the latest quarter, +24% on a year earlier.
Capital spending per quarter. Capital spending $415K in the latest quarter, +38% on a year earlier.
Institutional holders (13F filers). 146 13F filers reported holding it in the latest 13F quarter, -7.0% on a year earlier.
Lobbying spend. Lobbying spend: $190K published in the last 12 months (none in the 12 months before).

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: insider net buying (open market), h-1b/e-3 applications certified, federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
26 Mar 2026Lobbying filingnew lobbying registration (FEROX STRATEGIES)
26 Mar 2026Sharp changeFirst lobbying registration: first lobbying registration: ATRIUM THERAPEUTICS: new lobbying registration (FEROX STRATEGIES)
27 Feb 20268-K and other filingsDirector or officer change
27 Feb 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
30 Sep 2025Sharp changeShort interest spike: short interest spike, 22.2M vs usual 15.7M (2025-09-15); 1.9x the same period a year earlier
Revenue per quarter
Quarter ended 31 Mar 2025: $1.6M; public on 15 May 2026
Quarter ended 30 Jun 2025: $3.8M; public on 14 Aug 2026
Quarter ended 30 Sep 2025: $12.3M; public on 13 Nov 2026
Quarter ended 31 Mar 2026: $19.6M, +1148% on a year earlier; public on 15 May 2026
Quarter ended 30 Jun 2026: $3.0M, -22% on a year earlier; public on 14 Aug 2026
Quarter ended 30 Sep 2026: $15.3M, +24% on a year earlier; public on 13 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2025: $0; public on 15 May 2026
Quarter ended 30 Jun 2025: $266K; public on 14 Aug 2026
Quarter ended 30 Sep 2025: $300K; public on 13 Nov 2026
Quarter ended 31 Mar 2026: $2.1M; public on 15 May 2026
Quarter ended 30 Sep 2026: $415K, +38% on a year earlier; public on 13 Nov 2026
Institutional holders (13F filers)
31 Mar 2026 report: 157; public on 15 May 2026
30 Jun 2026 report: 153; public on 14 Aug 2026
30 Sep 2026 report: 146; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2026: $30K published
Quarter from 1 Jul 2026: $80K published
Quarter from 1 Oct 2026: $80K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is cash and cash equivalents at period end at $44.6M (30 Sep 2026), higher than 67% of its own history.
  • Revenue per quarter: Revenue $15.3M in the latest quarter, +24% on a year earlier.
  • Capital spending per quarter: Capital spending $415K in the latest quarter, +38% on a year earlier.
  • Institutional holders (13F filers): 146 13F filers reported holding it in the latest 13F quarter, -7.0% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

146 institutions reported shares at the end of Q3 2026, 65% of the shares outstanding; 22 opened a position, 32 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Sessa Capital IM, L.P.1.5M6.95%$12.4MNo change
BlackRock, Inc.1.2M5.65%$10.1M-229K-16%
Vanguard Capital Management LLC730K3.38%$6.0M-805-0.1%
T. Rowe Price Associates Inc640K2.97%-833K-57%
O'Connor Alternative Investments, LLC559K2.59%$4.6M-38K-6.3%
Bracebridge Capital, LLC524K2.43%$4.3M+385K+277%
TIG Advisors, LLC507K2.35%$4.2M-55K-9.7%
Bank of America Corp468K2.17%$3.9M+335K+252%
Two Sigma Investments, LP427K1.98%$3.5M+82K+24%
Geode Capital Management, LLC380K1.76%$3.1M-7,113-1.8%

Company events

All 3 company events

In 12 months: 2 major agreements, 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
8 Oct 2026Signed a major agreementSame filing: sold shares privately8-K
27 Feb 2026Director or officer change; Signed a major agreementSame filing: change of control8-K

Reported lobbying spend: $80K in Q3 2026, $80K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Mar 2026NewFerox Strategiesfor Atrium TherapeuticsGeneral issues related to rare disease pharmaceuticals.Health issues, PharmacyFiling

The 5 newest of 88 articles that name the company.

Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 26 Mar 2026Lobbying change

    registered for federal lobbying for the first time in our data (Ferox Strategies).

    See the evidence (1 source record)
    Source coverage starts
    4 Apr 2008
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  2. 26 Mar 2026Lobbying record

    ATRIUM THERAPEUTICS: new lobbying registration (FEROX STRATEGIES) (dated 1 Mar 2026)

  3. 27 Feb 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 27 Feb 2026Filings record

    Director or officer change

  5. 25 Sep 2025Short interest and volume change

    had 22.2M shares sold short in the 15 Sep 2025 report, 1.9× the same report last year.

    Same report last year: 12.0M; its normal report is 15.7M.

    See the evidence
    This period
    22.2M (the 15 Sep 2025 report)
    Normal report (median of 24 earlier)
    15.7M
    Typical spread (median absolute deviation)
    697K
    How far from its usual level
    +4.2
    Same report last year
    12.0M
    History used
    1,918 days
    2024-09-13: 12.0M2024-09-30: 14.8M2024-10-15: 14.9M2024-10-31: 14.7M2024-11-15: 14.5M2024-11-29: 14.9M2024-12-13: 15.5M2024-12-31: 15.7M2025-01-15: 15.4M2025-01-31: 14.9M2025-02-14: 16.5M2025-02-28: 17.0M2025-03-14: 16.1M2025-03-31: 17.6M2025-04-15: 15.5M2025-04-30: 15.6M2025-05-15: 15.8M2025-05-30: 16.2M2025-06-13: 16.3M2025-06-30: 16.7M2025-07-15: 16.3M2025-07-31: 16.2M2025-08-15: 15.7M2025-08-29: 17.6M2025-09-15: 22.2M
    the 15 Sep 2025 report24 earlier reportsnormal: 15.7M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Not listed: 12 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0002093101
Ticker
RNA
Domain
aviditybiosciences.com
Hq location
CA|SAN DIEGO| (1 unverified)
Lobbying client
atrium therapeutics
Name
Atrium Therapeutics, Inc.
  • Federal lobbying disclosures (LDA)1 record, 9 data points1 Mar 2026 to 30 Sep 2026
  • SEC Form 13F institutional holdings27 data points31 Mar 2026 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)13 records27 Feb 2026 to 12 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)84 data points31 Dec 2024 to 2 Nov 2026
  • FINRA short interest (twice monthly)457 data points15 Jun 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3238 data points12 Jun 2020 to 20 Nov 2026